Lantus vs Tresiba: A Practical Breakdown for Patients

Lantus at a glance:

• Drug class: Long-acting basal insulin analog
• Manufacturer: Sanofi
• FDA approved: 2000
• Route: subcutaneous injection (SoloStar pen or vial)
• Typical frequency: once daily, same time each day
• Half-life: ~12 hours (effective duration ~24 hours)
• Cash price (US): ~$280–$340/month list; $35/month cap for Medicare beneficiaries; biosimilar (Semglee) available at lower cost

Lantus comparison pages tend to overstate the differences. The honest take is that most well-established options in this space are similar enough that insurance coverage, prescriber familiarity, and personal preference matter more than head-to-head efficacy.

Mechanism

Lantus: Insulin glargine is a long-acting analog. After subcutaneous injection it forms microprecipitates that release slowly, producing a relatively flat 24-hour profile without a pronounced peak.

Tresiba: Insulin degludec forms soluble multi-hexamers in subcutaneous tissue that release slowly into circulation, producing a flat duration of action exceeding 42 hours.

For people new to this comparison, the practical takeaway is that the underlying mechanisms are different enough that response can vary.

Dosing & Administration

Effectiveness

Lantus: 24-hour basal glucose control with reduced nocturnal hypoglycemia vs NPH.

Tresiba: Comparable A1c reduction to glargine with significantly lower rates of nocturnal hypoglycemia (DEVOTE).

In head-to-head comparisons (where they exist), the higher-dose newer agents tend to outperform older ones — sometimes meaningfully. Reference trials: Riddle MC et al for Lantus; DEVOTE (Marso 2017, NEJM) — non-inferior cardiovascular safety vs glargine; 40% lower nocturnal severe hypoglycemia for Tresiba.

Side Effects

The two compounds have overlapping side-effect profiles. Common to both:

• hypoglycemia
• weight gain
• injection-site reactions
• lipodystrophy with poor rotation

Important risks worth knowing for both:

• severe hypoglycemia
• diabetic ketoacidosis if dosing is interrupted in T1D

Cost

Lantus: ~$280–$340/month list; $35/month cap for Medicare beneficiaries; biosimilar (Semglee) available at lower cost. Tresiba: ~$420–$480/month list; $35/month cap for Medicare beneficiaries.

Insurance coverage and manufacturer programs change the relative cost picture significantly. See our individual cost guides for Lantus cost and Tresiba cost for the latest numbers.

Which Is Right for You?

The practical decision usually comes down to four factors:

1. What's covered by your insurance? Often the deciding factor
2. What does your prescriber have experience with? Familiarity reduces dosing errors
3. How comfortable are you with injections (or oral dosing if applicable)?
4. What's your tolerance for side effects?

If you and your clinician end up split between Lantus and Tresiba, either is a defensible choice in most cases.

Switching Between Them

Switching from Lantus to Tresiba (or the reverse) is usually straightforward but should be done with clinician guidance — particularly to align dose escalation and avoid GI side effects from re-titration.

Bottom Line

Don't overthink the Lantus vs alternative decision. Both produce results; the difference is usually smaller than the discussion implies.

Frequently Asked Questions

Related Reading

• Is Lantus Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Lantus Side Effects
• Lantus Outcomes Decoded: Who Responds Best and Why
• How Much Does Lantus Really Cost? The Honest Breakdown
• What Is Humalog? Everything You Should Know Before Starting
• Lantus Dosing Patterns in the Research Literature

Sources

• American Diabetes Association. Standards of Care in Diabetes — 2024. Diabetes Care 2024;47(Suppl 1).
• Heise T et al. Insulin Pharmacokinetics and Pharmacodynamics. Diabetes Obes Metab 2017;19:3.

This page is informational only and is not a personalized recommendation. The right choice depends on your individual situation.